Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
Status:
Completed
Trial end date:
2017-09-28
Target enrollment:
Participant gender:
Summary
The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva®
Respimat®) in patients with severe persistent asthma under the real-world use was not
confirmed in clinical trials.